一种二价纳米颗粒疫苗对 SARS-CoV-2 的变异株表现出强大的交叉保护作用。
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.
机构信息
Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
Qianyang Biomedical Research Institute, Guangzhou, Guangdong 510063, China.
出版信息
Cell Rep. 2022 Jan 18;38(3):110256. doi: 10.1016/j.celrep.2021.110256. Epub 2021 Dec 23.
Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants.
全球范围内正在进行针对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的接种。然而，SARS-CoV-2 变体的出现可能导致免疫逃逸。我们开发了一种二价纳米颗粒疫苗，该疫苗展示了 D614G 和 B.1.351 株的受体结合域（RBD）。通过初免-加强或单剂策略，该疫苗在人血管紧张素转换酶 2 转基因小鼠中引发了针对真实 D614G 或 B.1.351 株感染的强大中和抗体和完全保护。有趣的是，接种 D614G 特异性疫苗 8 个月后，用这种二价疫苗进行新的加强免疫，可有效诱导恒河猴中针对 SARS-CoV-2 变体的交叉中和抗体。我们认为，D614G/B.1.351 二价疫苗可用作初始单剂量或序贯加强剂量，以预防 SARS-CoV-2 及其变体的感染。
Zotero 插件